9CD5
 
 | | FGFR1 Kinase Domain Soak with Inhibitor TYRA-300 | | Descriptor: | (3P)-5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-3-{6-[6-(methanesulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl]pyridin-3-yl}-1H-indazole, 1,2-ETHANEDIOL, Fibroblast growth factor receptor 1, ... | | Authors: | Hoffman, I.H, Nelson, K.J, Rideout, M.C, Frye, C, Bensen, D.C, Hudkins, R.L. | | Deposit date: | 2024-06-24 | | Release date: | 2024-09-25 | | Method: | X-RAY DIFFRACTION (2.939 Å) | | Cite: | Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
J.Med.Chem., 2024
|
|
9CD7
 | | FGFR3 Kinase Domain with Inhibitor TYRA-300 | | Descriptor: | (3P)-5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-3-{6-[6-(methanesulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl]pyridin-3-yl}-1H-indazole, Fibroblast growth factor receptor 3, GLYCEROL, ... | | Authors: | Hoffman, I.H, Nelson, K.J, Rideout, M.C, Nix, J.C, Frye, C, Bensen, D.C, Hudkins, R.L. | | Deposit date: | 2024-06-24 | | Release date: | 2024-09-25 | | Method: | X-RAY DIFFRACTION (2.53 Å) | | Cite: | Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
J.Med.Chem., 2024
|
|
